疑似死亡人数达101人！小林制药会长和社长双双辞职

近几个月，日本多人服用小林制药生产的含红曲成分保健品后，因肾脏疾病住院甚至死亡。截至7月21日，疑似相关死亡人数已达101人，在医疗机构就诊人数超2000人。

来源：小林制药官网

据日本共同社7月23日报道，日本小林制药公司当天公布了外部专家关于含红曲成分保健品的调查报告。报告中提到，生产工厂尽管了解到红曲培养罐有青霉附着，但放任不管。

外部专家还称，该公司在发现相关肾病病例后，面对医生的质询仍回答保健品“没有副作用”。专家在报告中批评了小林制药对消费者的说明滞后。提及小林制药公司会长小林一雅和社长小林章浩，报告中称其领导能力不足，没有作出率先确保消费者安全的判断和指示。

23日上午，小林制药召开临时董事会会议，小林一雅和小林章浩辞职。

Kobayashi Pharmaceutical, a household name in Japan, is at the centre of health fears linked to its over-the-counter tablets containing red yeast rice, which is fermented with a mould culture.

According to Kobayashi Pharmaceutical, the number of deaths that need to be investigated in connection with the consumption of its supplements reached 101 as of Sunday, including four people that the company announced in March that had died after taking its dietary supplements with red yeast rice, or beni-koji.

Kobayashi Pharmaceutical said president Akihiro Kobayashi and chairman Kazumasa Kobayashi were leaving their posts. Kobayashi Pharmaceutical’s new president is Satoshi Yamane, previously head of sustainability policy, the company said.